U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342738) titled 'TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors' on Jan. 05.
Brief Summary: This is a single-arm, Multicenter, open-label clinical study aimed at evaluating the safety and efficacy of TCR-T injection in patients with advanced solid tumors induced by KRAS mutations.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
KRAS G12V
KRAS G12D
Solid Tumor
Intervention:
BIOLOGICAL: TCR-T cells
TCR-T cell injection will be administered intravenously after lymphodepletion.
DRUG: Fludarabine
Fludarabine is used for lymphodepletion.
DRUG: Cyclophosphamide
Cyclophosphamide is used for lymphodepletion.
Recruit...